Modine Manufacturing Company vs Novavax Inc — how do they compare? Modine Manufacturing Company trades at $247 (market cap $12.18B), while Novavax Inc trades at $8.08 (market cap $1.30B). The key difference: Modine Manufacturing Company is far larger — about 9.4× Novavax Inc's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| MOD | NVAX | |
|---|---|---|
Market Cap | $12.18B | $1.30B |
Sector | Technology | Health |
52-Week High | $306.89 | $11.19 |
52-Week Low | $93.71 | $6.22 |
Enterprise Value | $12.54B | $800.50M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Trailing returns across standard periods
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →